Skip to content

A new investment fund promotes innovative projects in paediatrics

i4KIDS, the paediatric innovation hub coordinated by the Hospital Sant Joan de Déu, together with the private equity firm Ship2B Ventures, has launched the Montana Impact Fund to promote innovative projects in the field of paediatric health.
Montana Impact Fund

The fund has a first round of 30 million euros to invest in startups, either in early stage or spin offs, which are currently working on projects that search for:

– advancing in the prevention of childhood diseases, through preventive medicine and early diagnosis

– developing personalised treatments for paediatric patients

– promoting solutions to improve the quality of life of children who have overcome the disease and monitor side effects.

“At Sant Joan de Déu, as a paediatric and maternity hospital, our mission is to care for and cure the paediatric population and to work to ensure that all children and adolescents have access to the best diagnoses and treatments. Currently, there is a lack of tools to support various stages of the process of research, development and marketing of paediatric solutions. This has led us to participate in initiatives such as the Montana Impact Fund, which will help drive the arrival of new solutions for this segment of the population,” says Arnau Valls, director of i4KIDS.

“The Montana Impact Fund comes as a natural response to drive investment in paediatric innovation that puts the focus on children’s quality of life first. With Ship2B, we have been collaborating with Hospital Sant Joan de Déu for many years. For us, joining this project has been a natural reaction to share the same purpose,” says Maite Fibla, Co-Founder and managing partner of Ship2B Ventures.

According to Marc Ramis, venture partner of Ship2B Ventures, “the Montana fund is a fundamental tool that aligns the collective purpose of entrepreneurs, doctors, scientists and responsible investors who want to improve the quality of life of children. With its launch, it creates a unique and differentiated opportunity for impact investors in the health sector.”

The fund is currently in the process of registration with the CNMV and expects its first closing by the end of this year.

 

About the author
i4KIDS
Content by i4KIDS
Related News
i4KIDS Training Capsule

Uncategorized

i4KIDS and Catalonia.Health brought together startup leaders, researchers and healthcare professionals to discuss funding, regulatory strategy and international growth. The session featured Gisela Lorente (Aptadel Therapeutics), Marc Martinell (Minoryx Therapeutics) and Stefanos Theoharis (OneChain Immunotherapeutics), highlighting Barcelona's growing role as a leading hub for paediatric health innovation.
CogniTOT

Uncategorized

The European project i4KIDS-4RARE has selected CogniTOT, a language-independent digital cognitive assessment tool developed by Liltoda Ltd, as the winning solution of its Neuroepilepsy Innovation Programme. Validated in more than 1,000 children across ten countries, the tool will now enter a pilot phase within the EpiCARE network to assess its potential for the early detection and monitoring of cognitive impairment in children living with rare epilepsies.

Uncategorized

The i4KIDS Acceleration Programme 2026 has officially launched its new cohort, bringing together five high-potential projects that showcase the diversity and strength of paediatric innovation. From breakthrough therapies for rare diseases and childhood cancer to advanced medical technologies and digital solutions tailored for paediatric care, the selected initiatives address pressing unmet clinical needs. Through a structured training and mentoring pathway, the programme will support teams in advancing clinical validation, regulatory readiness, technology transfer and market access, with a strong focus on delivering sustainable solutions and tangible impact for children and families.